In conclusion, single-agent copanlisib demonstrated modest antilymphoma activity in patients with relapsed/refractory DLBCL with a numerically higher response rate in patients with ABC DLBCL vs. patients with GCB DLBCL, with similar activity in patients with and without CD79B mutations. Here, CD79B is linked to diffuse large B-cell lymphoma.